Evaluation of amphotericin B and micafungin combination against clinical isolates of Aspergillus species

Journal of Chemotherapy

Volumn 23, Issue 2, 2011, Pages 102-106

  Nishi, I ^a,b   Sunada, A ^a   Toyokawa, M ^a   Asari, S ^a   Iwatani, Y ^b  

^a OSAKA UNIVERSITY HOSPITAL   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Amphotericin B; Aspergillus species; Combination effect; Immunosuppression; Micafungin; Opportunistic infection; XTT

Indexed keywords

2,3 BIS (2 METHOXY 4 NITRO 5 SULPHOPHENYL) 2H TETRAZOLIUM 5 CARBOXYANILIDE INNER SALT; AMPHOTERICIN B; MICAFUNGIN; TETRAZOLIUM; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; FUNGUS GROWTH; GROWTH INHIBITION; IN VITRO STUDY; NONHUMAN;

EID: 80052715458     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2011.23.2.102     Document Type: Article

References (40)

1. Yoshimura N, Matsui S, Hamashima T, Oka T. Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. II. Inhibition of the production of IL-2 and gamma-IFN, but not B cell-stimulating factor 2. Transplantation 1989; 47 (2): 356-359.
2. Hzazi K, Le Maitre A, Hudes G, Berry WR, Kelly WK, Eymard JC et al. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol 2007;8 (11):994-1000.
3. Metzger DS, Zhang Y. Drug treatment as HIV prevention: expanding treatment options. Curr HIV/AIDS Rep 2010; 8 29.
4. Cornillet A, Camus C, Nimubona S, Gandemer V, Tattevin P, Belleguic C et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. Clin Infect Dis 2006; 43 (1): 577-584.
5. Rabkin JM, Oroloff SL, Corless CL, Benner KG, Flora KD, Rosen HR et al. Association of fungal infection and increased mortality in liver transplant recipients. Am J Surg 2000; 179 (5): 426-430.
6. Chou NK, Chi NH, Wu IW, Huang SC, Chen YS, Yu HY et al. Fungal infection in heart transplant recipients with severe sepsis: single-center experience. Transplant Proc 2010;42 (3): 952-954.
7. Gilbert DN, Moellering RC, Eliopoulos GM, Chambers HF, Saag MS, eds. The sanford guide to antimicrobial therapy 2010. 40 th ed. Sperryville: Antimicrobial therapy, Inc. 2010.
8. Robinson RF, Nahata MC. A comparative review of conventional and lipid formulations of amphotericin B. J Clinical Phann Thera 1999; 24 (4): 249-257.
9. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleiner-mans D. Pharmacokinetics and safety of voriconazole following intravenous-to oral-dose escalation regimens. Antimicrob Agents Chemother 2002; 46 (8): 2546-2553.
10. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA et al. Treatment of aspergillosis: Clinical practice guidelines of the Infectious diseases society of America. Clin Infect Dis 2008; 46: 327-360.
11. Denning DW, Baily GG, Hood S. Azole resistance in Candida. Eur J Clin Microbiol Infect Dis 1997; 16 (4): 261-280.
12. Eggimann P, Garbino J, Pittet D. Management of Candida species infections in critically ill patients. Lancet Infect Dis 2003; 3 (12): 772-785.
13. Garnacho-Montero J, Diaz-Martin A, Garcia-Cabrera E, Ruiz Perez de Pipaon M, Hernandez-Caballero C, Aznar-Martin C et al. Risk factors for fluconazole-resistant candidemia. Antimicrob Agents Chemother 2010; 54(8): 3149-3154.
14. Verweij PE, Snelders E, Kema GH, Mellado E, Melchers WJ. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect Dis. 2009; 9 (12):789-795.
15. Bueid A, Howard SJ, Moore CB, Richardson MD, Harrison E, Bowyer P et al. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J Antimicrob Chemother 2010; 65 (10):2116-2118.
16. Johnson MD, MacDougall C, Ostrosky-Zeichner L, Perfect JR, Rex JH. Combination antifungal therapy. Antimicrob Agents Chemother 2004; 48 (3): 693-715.
17. Krogstad DJ, Moellering RC. Antimicrobial combinations. Antibiotics in laboratory medicine. 2nd ed. Baltimore: Williams & Wilkins. 1986: 537-595.
18. Toyakawa M, Asari S, Nishi I, Horikawa M, Tsukamato H, Sunada A et al. In vitro combined effect of cefozopran/teicoplanin and cefozopran/ vancomycin on methicillin-resistant Staphylococcus aureus. J Chemother 2003; 15(1): 31-36.
19. Nishi I, Sunada A, Toyokawa M, Asari S, Iwatani Y. In vitro antifungal combination effects of micafungin with fluconazole, voriconazole, amphotericin B, and flucytosine against clinical isolates of Candida species. J Infect Chemother 2008; 15 (1): 1-5.
20. Arikan S, Lozano CM, Paetznick V, Rex HJ. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002; 46 (1): 245-247.
21. Dannaoui E, Lortholary O, Dromer F. In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus. Antimicrob Agents Chemother 2004; 48 (3): 970-978.
22. Cuenca EM, Gomez LA, Garcia EG, Alcazar FL, Mellado E, Buitrago JM et al. Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazoleresistant clinical isolates of Aspergillus fumigates. Antimicrob Agents Chemother 2005; 49 (3): 1232-1235.
23. Procop GW, Roberts GD. Laboratory methods in basic mycology. Diagnostic Microbiology. 10th ed. St. Louis: Mosby. 1998: 871-961.
24. Antachopoulos C, Meletiadis J, Sein T, Roilides E, Walsh TJ. Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species. Antimicrob Agents Chemother 2007; 51 (3): 881-887.
25. Clinical Laboratory Standards Institute (CLSI) Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard 2nd ed. CLSI document M38-A2. Wayne, PA: CLSI 2008; 28: 135.
26. Denning DW. Echinocandin antifungal drugs. The Lancet 2003; 362: 1142-1151.
27. Roehm NW, Rodgers GH, Hatfield SM, Glasebrook AL. An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. J Immuno Methods 1991; 142 (2): 257-265.
28. Franzot SP, Casadevall A. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neofor-mans in vitro. Antimicrob Agents Chemother 1997; 41 (2): 331-336.
29. Meletiadis J, Mouton JW, Meis JFGM, Bouman BA, Donnelly JP, Ver-weij PE. Colorimetric assay for antifungal susceptibility testing of Aspergillus species. J Clin Microbiol 2001; 39 (9): 3402-3408.
30. Yekutiel A, Shalit I, Shadkchan Y, Osherov N. In vitro activity of caspofungin combined with sulfamethoxazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 2004; 48 (9): 3279-3283.
31. Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S et al. In vitro susceptibility of clinical isolates of Aspergillus spp. to anidula-fungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method. J Clin Microbiol 2009; 47 (10): 3323-3325.
32. Baddley JW, Marr KA, Andes DR, Walsh TJ, Kauffman CA, Kon-toyiannis DP et al. Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the transplant-associated infection surveillance network. J Clin Microbiol 2009; 47 (10): 3271-3275.
33. Barwicz J. Tancrede P. The effect of aggregation state on ampho-tericin-B on its interactions with cholesterol-or ergosterol-containing phosphatidylcholine monolayers. Chem Phys Lipids 1997; 85(2): 145-155.
34. Baddley JW, Pappas PG, Smith AC, Moser SA. Epidemiology of Aspergillus terreus at a university hospital. J Clin Microbiol 2003; 41 (12): 5525-5529.
35. Lass-Flórl C, Alastruey-Izquierdo A, Cuenca-Estrella M, Perkhofer S, Rodriguez-Tudela JL. In vitro activities of various antifungal drugs against Aspergi//us terreus: Global assessment using the methodology of the European committee on antimicrobial susceptibility testing. Antimicrob Agents Chemother 2009; 53 (2): 794-795.
36. Takazono T, Izumikawa K, Mihara T, Kosai K, Saijo T, Imamura Y et al. Efficacy of combination antifungal therapy with intraperitoneally administered micafungin and aerosolized liposomal amphotericin B against murine invasive pulmonary Aspergillosis. Antimicrob Agents Chemother 2009; 53 (8): 3508-3510.
37. Dennis CG, Greco WR, Brun Y, Youn R, Slocum HK, Bernacki RJ et al. Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-/-mouse model of chronic granulomatous disease. Antimicrob Agents Chemother 2006; 50 (2): 422-427.
38. Meletiadis J, Antachopoulos C, Stergiopoulou T, Pournaras S, Roilides E, Walsh TJ. Differential fungicidal activities of amphotericin B and voriconazole against Aspergillus species determined by microbroth methodology. Antimicrob Agents Chemother 2007; 51 (9): 3329-3337.
39. Antachopoulos C, Meletiadis J, Sein T, Roilides E, Walsh TJ. Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia Antimicrob Agents Chemother 2008; 52 (1): 321-328.
40. Wiederhold NP. Paradoxical echinocandin activity: a limited in vitro phenomenon? Med Mycol 2009; 47 (Suppl 1): S369-375.